SGLT2i Use Has Lower Pneumonia Risk vs DPP4i in Type 2 Diabetes - Endocrinology Advisor
Sodium-glucose cotransporter 2 inhibitor (SGLT2i) use is associated with a significantly reduced risk of pneumonia and pneumonia mortality compared with dipeptidyl peptidase-4 inhibitor (DPP4i) use in people w…
Read guide →